PHENYTEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Phenytex, and when can generic versions of Phenytex launch?
Phenytex is a drug marketed by Watson Labs and is included in one NDA.
The generic ingredient in PHENYTEX is phenytoin sodium. There are twenty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the phenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenytex
A generic version of PHENYTEX was approved as phenytoin sodium by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for PHENYTEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 155 |
Patent Applications: | 395 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PHENYTEX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PHENYTEX
US Patents and Regulatory Information for PHENYTEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | PHENYTEX | phenytoin sodium | CAPSULE;ORAL | 088711-001 | Dec 21, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |